Clinical Trials Browser

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

ICON

BELLINI

BreastImmune03

Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

ROME

Immunological Variables Associated to ICI Toxicity in Cancer Patients

CheckMate 7A8

TONIC

TONIC-2

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

CONTESSA TRIO

GIADA

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer